Skip to main content
SpringerLink
Log in

Antiandrogene in der Therapie des fortgeschrittenen Prostatakarzinoms

  • Conference paper
Book cover Konservative Therapie des Prostatakarzinoms

Zusammenfassung

Antiandrogene sind als Substanzen definiert, die die Wirkung von Androgenen am Erfolgsorgan neutralisieren. Prinzipiell sind 2 Typen von Antiandrogenen zu differenzieren:

  • das steroidale Antiandrogen vom Cyproteronacetat-Typ und das nichtsteroidale Antiandrogen vom Flutamid-Typ.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arnhold J, Bingold M, Tunn UW (1986) Transrectale Prostatasonographie — ein prognostisches Kriterium beim Prostatakarzinom? Verh Dtsch Ges Urol, 37. Tagung, Mainz. Thieme, Stuttgart New York, S 529

    Google Scholar 

  2. Bingold M, Arnhold J, Tunn UW (1987) Cytostase als primäre oder sekundäre Therapie des fortgeschrittenen Prostatakarzinoms? Verh Dtsch Ges Urol, 38. Tagung, Würzburg, im Druck

    Google Scholar 

  3. Bracci U (1979) Antiandrogens in the treatment of prostatic cancer. Eur Urol 5: 303–306

    PubMed  CAS  Google Scholar 

  4. Geller J, Vazakas G, Fruchtman B, Newman H, Nakao K, Loh A (1986) The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 127 /4: 748–758

    Google Scholar 

  5. Giulani L, Pescatore D, Gilberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy-5-year-follow-up. Eur Urol 6: 145–148

    Google Scholar 

  6. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17

    Article  PubMed  CAS  Google Scholar 

  7. Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral cyproterone acetate: A phase III randomised trial. Brit J Urol 52: 208

    Google Scholar 

  8. Jacobi GH, Tunn UW, Senge TH (1982) Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer. In: Jacobi GH, Hohenfellner R (EDS) Prostate Cancer. Williams & Wilkins, Baltimore London, PP 305–319

    Google Scholar 

  9. Jacobi GH (1983) Intramuscular cyproterone acetate treatment for advanced prostatic carcinoma: results of the first multicentric randomized trial. In: Schröder FH (ed) Androgens and Antiandrogens, International Symposium June 5th, 1982. Schering Nederland BV

    Google Scholar 

  10. Karr JP, Murphy GP (1983) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Bruchovsky N, Chapdelaine A, Neumann F, Brückner R (eds) Regulation of Androgen Action. Berlin, S 81–86

    Google Scholar 

  11. Klosterhalfen H, Becker H (1983) Antiandrogentherapie des Prostatakarzinoms — Klinische Erfahrungen mit Androcur/Androcur-Depot. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. Vortragsveranstaltung für Urologen, Berlin 1982/83. Med Wiss Buchreihe, Schering AG, Berlin, S 63–65

    Google Scholar 

  12. Labrie F, Dupont A, Belanger A, Lacoursiere, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–594

    Article  PubMed  CAS  Google Scholar 

  13. Murphy GP, Huben RP, Priore R (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metatastatic prostate cancer. Urology XXVIII: 36–40

    Google Scholar 

  14. Nagel R, Leistenschneider W (1983) Chemotherapie des Prostatakarzinoms. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms, Med Wiss Buchreihe, Schering AG, 55–62

    Google Scholar 

  15. Page JP, Levi JA, Woods RL, Tattersall MN, Fox RM, Coates AS (1985) Randomized trial of combination chemotherapy in hormone resistant metastatic prostate carcinoma. Cancer Treat Rep 69 /1: 105–107

    PubMed  CAS  Google Scholar 

  16. Pavone-Macaluso M and EORTC-GU-Group (1982) Medroxyprogesterone acetate, diethylstil-boestrol and cyproterone acetate in the treatment of prostatic cancer. Interim report of a prospective study of the European Orgazination for Research on the Treatment of Cancer (EORTC). Genitourinary Tract Cooperative Group — Excerpt Medicae Int Congr Ser 611: 436–444

    Google Scholar 

  17. Pescatore D, Giberti C, Mortorana G, Natta G, Giuliani L (1980) The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer. Eur Urol 6: 149–153

    PubMed  CAS  Google Scholar 

  18. Sander S, Nissen-Meyer R, Aakvaag A (1982) Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study. Scand J Urol Nephrol 16: 193

    Google Scholar 

  19. Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR, Loening S, Soloway M, De Kernion H, Pontes JE, Slack NH, Murphy GP (1980) Chemotherapy programs of the National Prostatic Cancer Projekt ( NPCP ). Cancer 45: 1937–1946

    Google Scholar 

  20. Scott WW, Schirmer HK (1966) A new oral progestional steroid effective in treating prostatic cancer. Trans Am Assoc Genitourin Surg 58: 54–60

    PubMed  CAS  Google Scholar 

  21. Servadio C, Mukamel E, Lurie H, Nissenkorn I (1983) Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology XXI /5: 492–495

    Google Scholar 

  22. Sogani PC, Vagaiwala MR & Whitmore WF (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744–750

    Article  PubMed  CAS  Google Scholar 

  23. Tunn UW, Senge Th, Jacobi GH (1983a) Klinische Erfahrungen mit Cyproteronacetat als Monotherapie beim inoperablen Prostatakarzinom. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. Vortragsveranstaltung für Urologen, Berlin 1982/83. Med Wiss Buchreihe, Schering AG, Berlin, S 67–76

    Google Scholar 

  24. Tunn UW, Graff J, Senge Th ( 1983 b) Treatment of inoperable prostatic cancer with cyproterone acetate. In: Schröder FH (ed) Androgens and anti-androgens. Schering Nederland BV, S 149–159

    Google Scholar 

  25. De Voogt HH, EORTC-GU-Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on the Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307

    Google Scholar 

Download references

Authors
  1. U. W. Tunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. im Klinikum Charlottenburg, Freie Universität Berlin, Spandauer Damm 130, D-1000, Berlin 19, Germany

    Reinhard Nagel (Direktor Urologische Klinik und Poliklinik) (Direktor Urologische Klinik und Poliklinik)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Tunn, U.W. (1987). Antiandrogene in der Therapie des fortgeschrittenen Prostatakarzinoms. In: Nagel, R. (eds) Konservative Therapie des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72613-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72613-2_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17724-1

  • Online ISBN: 978-3-642-72613-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation